Pharmaceutical Biocatalysis : (Record no. 126331)

000 -LEADER
fixed length control field 03469cam a2200529Ki 4500
001 - CONTROL NUMBER
control field 9780429295034
003 - CONTROL NUMBER IDENTIFIER
control field FlBoTFG
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220509192916.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cnu|||unuuu
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 190701s2019 si ob 001 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency OCoLC-P
Language of cataloging eng
Description conventions rda
-- pn
Transcribing agency OCoLC-P
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780429295034
-- (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 0429295030
-- (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781000021110
-- (electronic bk. : Mobipocket)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1000021114
-- (electronic bk. : Mobipocket)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781000021288
-- (electronic bk. : EPUB)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1000021289
-- (electronic bk. : EPUB)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781000020946
-- (electronic bk. : PDF)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1000020940
-- (electronic bk. : PDF)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 9789814800617
024 8# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1201/9780429295034
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)1106526045
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC-P)1106526045
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number TP248.E5
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 009000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 014000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 071000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code TDCW
Source bicssc
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 660.6/34
Edition number 23
245 00 - TITLE STATEMENT
Title Pharmaceutical Biocatalysis :
Remainder of title Fundamentals, Enzyme Inhibitors, and Enzymes in Health and Diseases /
Statement of responsibility, etc edited by Peter Grunwald.
264 #1 -
-- Singapore :
-- Jenny Stanford Publishing,
-- 2019.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
490 1# - SERIES STATEMENT
Series statement Jenny Stanford series on biocatalysis ;
Volume number/sequential designation volume 4
520 ## - SUMMARY, ETC.
Summary, etc This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-designer approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.
588 ## -
-- OCLC-licensed vendor bibliographic record.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Enzymes
General subdivision Industrial applications.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical biotechnology.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element MEDICAL / Biotechnology
Source of heading or term bisacsh
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element MEDICAL / Clinical Medicine
Source of heading or term bisacsh
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element MEDICAL / Pharmacology
Source of heading or term bisacsh
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Grunwald, Peter.
856 40 - ELECTRONIC LOCATION AND ACCESS
Materials specified Taylor & Francis
Uniform Resource Identifier https://www.taylorfrancis.com/books/9780429295034
856 42 - ELECTRONIC LOCATION AND ACCESS
Materials specified OCLC metadata license agreement
Uniform Resource Identifier http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue